By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Santaris Pharma A/S (Formerly Pantheco A/S) 

Danish Science Park
Bøge Alle 3
Hørsholm    DK 2970  Denmark
Phone: 45-4517-9800 Fax: 45-4517-9898



Company News
Roche (RHHBY) Bags Santaris Pharma A/S In Deal Worth $450 Million 8/4/2014 9:52:10 AM
Danish Drug Maker Santaris Pharma A/S Considers U.S. Listing 3/27/2014 7:18:12 AM
Santaris Pharma A/S, Roche (RHHBY) Strike $148 Million+ Alliance To Design And Develop RNA-Targeted Drugs 1/10/2014 7:34:21 AM
Santaris Pharma A/S, GlaxoSmithKline (GSK) Forges Pact To Develop RNA-Targeted Medicines, Financial Details Not Disclosed 1/10/2014 7:03:37 AM
Isarna Therapeutics And Santaris Pharma A/S Announce License Agreement For The Development Of Next Generation Oligonucleotides To Treat TGF-Beta-Mediated Diseases 1/8/2014 9:52:47 AM
Santaris Pharma A/S Announces Appointment Of J. Donald Debethizy As President And Chief Executive Officer 1/8/2014 8:13:54 AM
Santaris Pharma A/S Resumes Full Ownership of Cancer Programs Licensed to Enzon Pharmaceuticals, Inc. (ENZN) 10/28/2013 10:21:35 AM
Shire plc and Shire Pharmaceuticals (SHPG) Extends Existing Rare Genetic Disease Pact 8/23/2013 7:09:38 AM
RaNA Therapeutics, Inc. and Santaris Pharma A/S Announce Agreement to develop RNA-Targeted Medicines That Selectively Activate Protein Expression 7/8/2013 10:16:23 AM
Santaris Pharma A/S Release: EPO Appeal Board Decides in Favor of the Wengel LNA Patent 4/18/2013 9:51:27 AM